Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

Phase 2positivePositive

AI Analysis

Summary

Cardiol Therapeutics published Phase II recurrent pericarditis data in the Journal of the American Heart Association, strengthening the foundation for its pivotal Phase III MAVERIC trial which is nearing completion.

Clinical Trial Data

Phase

Phase II

Outcome Details

Phase II Recurrent Pericarditis data published in peer-reviewed Journal of the American Heart Association

Importance:6/10

Sentiment:

0.70

Phase II DataPeer-Reviewed PublicationRecurrent PericarditisMAVERIC Phase IIIClinical Trial

Related Companies

$CRDL

Read the original article

Published by PR Newswire Clinical Trials on July 14, 2026 11:27 AM

Read Original